Therapeutic payload and delivery: Innovations to unlock new potential

Technology advances to help your success in the clinic

5

December

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

The webinar will cover three key topics, each addressing different aspects of gene delivery and gene editing. ​

​The first topic is AAV evolution. Our presenter will explain its importance in gene therapy and showcase recent project developments, including data from ophthalmology, insights into novel capsids and nanobody data.  ​

​The second presentation will focus on how transduction efficiency can be improved, how lentiviral manufacturing costs can be reduced using the LentBOOST TM enhancer technology, its advantages over other enhancers and how it integrates into existing processes, along with a review of relevant safety data. ​

​In the third presentation, we’ll explore gene editing technologies, including base editing, CRISPR, and prime editing. We will compare the different approaches, explain the unique advantages of Revvity’s Pin-pointTM base editing platform, and discuss clinical applications. Additional topics will include the use of transient effectors like shRNA and the SMARTvector multiplex system, clarifying when to use each approach for specific therapeutic needs. ​

​The webinar will conclude with a Q&A session to address audience questions.​

Learning Objectives: 

  • ​​How advancements in AAV evolution are helping to drive potency and lower doses / dosages ​
  • ​​​How to drive down manufacturing costs with LentBOOST TM transduction enhancer.​​
  • ​​Why different gene editing and modulation approaches are needed to expedite the next generation of advanced cell and gene therapies​.

​​Explore how Revvity’s gene delivery technologies can be integrated into therapeutic development.​

Speakers

Select a speaker to learn more

Back
Michelle Fraser
Head of Cell and Gene Therapy, Revvity

Michelle is the Head of Cell and Gene Therapy at Revvity. In this role, Michelle steers the strategic direction and influences how Revvity showcases its diverse array of CGT capabilities, across products, contracted services and technology licensing, to facilitate the advancement and launch of innovative cell and gene therapies. Michelle has a PhD in mycology and a Graduate Diploma in Science and Technology Commercialization from the University of Adelaide. She was previously manager of Revvity’s base editing business and our next generation sequencing product portfolio. 

Next speaker
Back
Janina Haar
Sr. Scientist, Revvity

Janina Haar is a trained virologist and molecular biologist who holds a PhD from the German Cancer Research Center (DKFZ) and Ruperto Carola University of Heidelberg. After completing her PhD, Janina joined the laboratory of Prof. Dirk Grimm as a Postdoc where she was the leading scientist within an industry collaboration aiming at the development of improved liver-tropic AAV capsids for hemophilia treatment. She transitioned to industry for a second Postdoc at Boehringer Ingelheim where she focused on the optimization of inducible gene expression cassettes for AAV-based gene therapy. Subsequently, Janina worked for Vector BioPharma AG in Basel as Senior Scientist developing adenoviral vectors for immuno-oncology applications and further exploring regulatable gene therapies. Janina joined Revvity in April 2024, where she is currently leading the laboratory team at the Heidelberg site of Revvity Gene Delivery and supporting our collaborations for AAV-based gene therapy development. 

Next speaker
Back
Amanda Haupt
Base Editing Business Manager, Revvity

Amanda Haupt is the Base Editing Business Unit Manager at Revvity. During her years here she has contributed as an R&D Scientist to the company’s portfolio of gene editing reagents. Today, Amanda supports commercialization of Revvity’s Pin-point™ base editing technology. 

Next speaker
Back
Benjamin Eberhardt
Product Manager, LentiBOOST

Benjamin is the Product Manager for the LentiBOOST™ technology at Revvity Gene Delivery, formerly SIRION Biotech. In this role, he maintains close connections with users, partners, and licensees who employ the technology in clinical trials. Benjamin collaborates with all relevant internal and external stakeholders to support the primary goal of making this technology accessible to scientists and, ultimately, to patients. He holds a Master of Science degree in Biology, with a focus on Microbiology and Medical Biology.

 

Next speaker

Enquiry